An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events

References

• Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117:238–249.
   PubMed Web of Science ®Google Scholar
• Albayrak M, Gursel T, Kaya Z, et al. Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia. Clin Appl Thromb Hemost. 2013;19:644–651.
   PubMed Web of Science ®Google Scholar
• De Stefano V, Za T, Ciminello A, et al. Haemostatic alterations induced by treatment with asparaginases and clinical consequences. Thromb Haemost. 2015;113:247–261.
   PubMed Web of Science ®Google Scholar
• Appel IM, Hop WC, van Kessel-Bakvis C, et al. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. Thromb Haemost. 2008;100:330–337.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99:1986–1994.
   PubMed Web of Science ®Google Scholar
• Caruso V, Iacoviello L, Di CA, et al. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost. 2007;5:621–623.
   PubMed Web of Science ®Google Scholar
• Kieslich M, Porto L, Lanfermann H, et al. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2003;25:484–487.
   PubMed Web of Science ®Google Scholar
• Caruso V, Iacoviello L, Di CA, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108:2216–2222.
   PubMed Web of Science ®Google Scholar
• Qureshi A, Mitchell C, Richards S, et al. Asparaginase-related venous thrombosis in UKALL 2003 – re-exposure to asparaginase is feasible and safe. Br J Haematol. 2010;149:410–413.
   PubMed Web of Science ®Google Scholar
• Truelove E, Fielding AK, Hunt BJ. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia. 2013;27:553–559.
   PubMed Web of Science ®Google Scholar
• Zuckerman T, Ganzel C, Tallman MS, et al. How I treat hematologic emergencies in adults with acute leukemia. Blood. 2012;120:1993–2002.
   PubMed Web of Science ®Google Scholar
• Imamura T, Morimoto A, Kato R, et al. Cerebral thrombotic complications in adolescent leukemia/lymphoma patients treated with L-asparaginase-containing chemotherapy. Leuk Lymphoma. 2005;46:729–735.
   PubMed Web of Science ®Google Scholar
• Santoro N, Colombini A, Silvestri D, et al. Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis: an AIEOP experience. J Pediatr Hematol Oncol. 2013;35:348–355.
   PubMed Web of Science ®Google Scholar
• Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14:199–209.
   PubMed Web of Science ®Google Scholar
• Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189–3197.
   PubMed Web of Science ®Google Scholar
• Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157:463–471.
   PubMed Web of Science ®Google Scholar
• Fielding AK. CRUK – UCL UKALL14 trial ClinicalTrials.gov Identifier: NCT01085617. [cited 2015 Mar 30]. Available from: http://clinicaltrials.gov/ct2/show/NCT01085617?term=UKALL14&rank =1.
   Google Scholar
• Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116–1123.
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Kuhn N, Wolff JE, et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol. 1996;56:35–38.
   PubMed Web of Science ®Google Scholar
• Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost. 2003;90:235–244.
   PubMed Web of Science ®Google Scholar
• Meister B, Kropshofer G, Klein-Franke A, et al. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50:298–303.
   PubMed Web of Science ®Google Scholar
• Ranta S, Heyman MM, Jahnukainen K, et al. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis. 2013;24:749–756.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Wolf RC, Hook CC, et al. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma. 2004;45:1545–1549.
   PubMed Web of Science ®Google Scholar
• Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008;93:1488–1494.
   PubMed Web of Science ®Google Scholar
• van den Berg H. Asparaginase revisited. Leuk Lymphoma. 2011;52:168–178.
   PubMed Web of Science ®Google Scholar
• Lauw MN, Van der Holt B, Middeldorp S, et al. Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: effect of fresh frozen plasma supplementation. Thromb Haemost. 2013;109:633–642.
   PubMed Web of Science ®Google Scholar